Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Epithelial ovarian cancer is the most fatal gynecological malignancy. Despite initial
therapeutic response, the majority of advanced-stage patients relapse and eventually succumb
to chemoresistant disease. The prognosis of patients with platinum-resistant or refractory
ovarian cancer was very poor, with the response rate of 20%~25% after chemotherapy. The
purpose of treatment for recurrent ovarian cancer is mainly to improve the quality of life of
patients and prolong survival. Angiogenesis is essential for tumor growth and metastasis.And
VEGF/VEGF receptor(VEGFR) signaling pathway is the most promising angiogenic target due to
its key roles in angiogenesis and tumor growth.This study sought to assess the efficacy and
safety of the combination therapy of apatinib and PLD, clarifying whether combination therapy
could improve the outcomes of patients with platinum-resistant recurrent ovarian cancer.